AkzoNobel, Axalta get week to address UK regulator concerns over $25 billion merger

By Reuters News

- Dulux paint maker AkzoNobel AKZO.AS and US peer Axalta's AXTA.N $25 billion merger raises competition concerns in the UK vehicle refinish coatings market, Britain's competition watchdog said on Wednesday, giving them a week to offer remedies or face a deeper probe.

The companies announced the deal in November last year as part of a wave of consolidation in the sector, which faces rising costs and uncertainties created by US tariffs.

The Competition and Markets Authority found in its initial probe that the merger would create a clear UK market leader in vehicle refinish coatings, the paints used by repair centres and bodyshops to fix and repaint damaged vehicles, with a combined share of 40% to 50% of supply.

The regulator said the two companies compete closely in the UK, offering similar products, technical support and holding extensive vehicle manufacturer and insurer approvals, and that losing one could lead to higher prices or reduced quality and support for customers.

The CMA gave the companies until November 18 to offer remedies or face an in-depth Phase 2 investigation.

AkzoNobel and Axalta aim to address the CMA's concerns with the same remedy proposal that was included in the European Commission decision, the companies said in a statement, reiterating that they remain confident of completing the merger by early 2027.

The companies secured approval for the merger from the European Union last week after AkzoNobel agreed to sell its vehicle refinish coatings business in Europe and the UK to address the regulator's competition concerns.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk